Nucleic Acid Aptamer for Rodent IgG Detection

The patent uses aptamers (nucleic acid molecules) as copies or alternatives to rodent-derived IgG antibodies. These aptamers are selected through SELEX (Systematic Evolution of Ligands by EXponential enrichment) to bind specifically to target antigens, replicating the binding function of antibodies without requiring complex animal immunization and antibody purification processes. The aptamers maintain high binding specificity while being easier to produce and handle.

The patent replaces rodent-derived IgG antibodies with aptamers that copy their binding function. Aptamers are nucleic acid molecules that can be easily stored, stabilized, and manipulated without the handling complexities associated with protein antibodies. They are more stable under various conditions and do not require the same level of careful handling, thus improving ease of operation while maintaining binding specificity.

The patent employs SELEX (Systematic Evolution of Ligands by EXponential enrichment) to iteratively optimize aptamer sequences and structures. Through multiple rounds of selection and amplification, aptamers with progressively higher binding affinity to the target antigen are obtained. This parameter optimization process ensures that the final aptamers achieve binding affinity comparable to or exceeding that of rodent-derived IgG antibodies, while maintaining the production and handling advantages of nucleic acid molecules.